Q1 2026E is set to show improving profitability in Technology & Distribution, while Energy & Environ...
Redeye has opened an Analyst Q&A following the recent share price movement and unusually high tradin...
* Clear initiatives for efficiency gains presented * Focus on add-on sales and M&A to re-accelerate ...
Efter en omfattande turnaround med stärkta marginaler och pressade returgrader har Nelly Group trans...
Last evening, Insplorion communicated a higher bid for its core business from Consilium, totaling ap...
Redeye provides an update on Biovica following the Q3 2025/2026 report, which overall came in slight...
Redeye comments on Better Collective’s announcement of expansion into prediction markets with the la...
Genovis announces a strategic partnership with Dutch CRO Single Cell Discoveries.
* A directed share issue adds MSEK 4.2 before costs * First patient enrolment expected as next trigg...
Agtira står inför ett skifte mot lönsam tillväxt efter förvärvet av Pepino.
Redeye comments on AlzeCure Pharma presenting new preclinical data for NeuroRestore ACD856 at the AD...
Enviro has signed a non-binding LOI regarding licensing of its pyrolysis technology in North America...
Redeye is encouraged by FluoGuide receiving FDA Fast Track Designation for FG001 in High-Grade Gliom...
Fluoguide announced that FG001 has been awarded FDA Fast Track designation, in a major validation of...
Redeye is positive to AAC’s press release today, which states an expected order value of more than E...
Redeye provides an initial comment on BioVica’s Q3 2025/2026 report.
Lower volumes mask an improved earnings profile, as Alcadon benefits from exiting its loss-making Ge...
Seafire enters 2026 with improving earnings momentum, supported by operational initiatives implement...
Redeye comments on Sprint Bioscience's announcement of positive preclinical proof-of-concept data fo...
Redeye briefly comments on Isofol setting the final terms for the exercise of its TO1 warrants issue...
